Mark Klang

ORCID: 0000-0002-8753-9783
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Melanoma and MAPK Pathways
  • Advanced Breast Cancer Therapies
  • Prostate Cancer Treatment and Research
  • Estrogen and related hormone effects
  • Clinical Nutrition and Gastroenterology
  • HER2/EGFR in Cancer Research
  • Cancer Research and Treatments
  • CAR-T cell therapy research
  • Pharmaceutical studies and practices
  • Invertebrate Taxonomy and Ecology
  • Computational Drug Discovery Methods
  • Clostridium difficile and Clostridium perfringens research
  • Botulinum Toxin and Related Neurological Disorders
  • Histone Deacetylase Inhibitors Research
  • Childhood Cancer Survivors' Quality of Life
  • Cancer, Lipids, and Metabolism
  • Hate Speech and Cyberbullying Detection
  • Child Nutrition and Feeding Issues
  • Central Venous Catheters and Hemodialysis
  • Safe Handling of Antineoplastic Drugs
  • Hormonal and reproductive studies
  • Lymphatic System and Diseases
  • Pancreatic and Hepatic Oncology Research
  • Immune cells in cancer
  • Bacterial Identification and Susceptibility Testing

American Society for Parenteral and Enteral Nutrition
2023-2024

Liechtenstein Institute
2024

John Wiley & Sons (United States)
2023-2024

Hudson Institute
2023-2024

Memorial Sloan Kettering Cancer Center
2009-2023

Cornell University
2003-2023

Core Laboratories (United States)
2023

Kettering University
2010

Abstract Continued reliance on the androgen receptor (AR) is now understood as a core mechanism in castration-resistant prostate cancer (CRPC), most advanced form of this disease. While established and novel AR pathway–targeting agents display clinical efficacy metastatic CRPC, dose-limiting side effects remain problematic for all current agents. In study, we report discovery development ARN-509, competitive inhibitor that fully antagonistic to overexpression, common important feature CRPC....

10.1158/0008-5472.can-11-3948 article EN Cancer Research 2012-01-21

Enteral nutrition (EN) is a valuable clinical intervention for patients of all ages in variety care settings. Along with its many outcome benefits come the potential adverse effects. These safety issues are result complications and process-related errors. The latter can occur at any step from patient assessment, prescribing, order review, to product selection, labeling, administration. To maximize EN while minimizing events requires that systematic approach be place. This includes open...

10.1177/0148607116673053 article EN Journal of Parenteral and Enteral Nutrition 2016-11-04

Intratumorally injected Clostridium novyi-NT (nontoxic; lacking the alpha toxin), an attenuated strain of C. novyi, replicates within hypoxic tumor regions resulting in tumor-confined cell lysis and inflammatory response animals, which warrants clinical investigation.This first-in-human study (NCT01924689) enrolled patients with injectable, treatment-refractory solid tumors to receive a single intratumoral injection across 6 dose cohorts (1 × 104 3 106 spores, 3+3 dose-escalation design)...

10.1158/1078-0432.ccr-20-2065 article EN Clinical Cancer Research 2020-10-12

When selecting medication for feeding tube administration, the liquid formulation is selected, so as to avoid obstructions that may occur from incompletely crushing a solid dosage form. Liquid medications can present issues of intolerance and compatibility when administered via tube. A predictor liquid's osmolarity, predicator pH value. This study examines 62 formulations their osmolality, pH, physical with enteral nutrition (EN) formulas. These were selected being most commonly dispensed...

10.1177/0148607112471560 article EN Journal of Parenteral and Enteral Nutrition 2013-01-17

A study was conducted to determine safety and efficacy of L‐glutamine when added total parenteral nutrition (TPN) solutions patients receiving TPN in the home. Stability studies were first performed on various concentrations mixed by Pharmix method. These showed that glutamine stable home for at least 22 days. The daily seven then supplemented with a dose 0.285 g/kg body weight 4 weeks. glutamine‐TPN prepared weekly. Five received full weeks glutamine‐TPN. In two patients, administration...

10.1177/0148607194018003268 article EN Journal of Parenteral and Enteral Nutrition 1994-05-01

Background Dysgeusia is a common but understudied complication in patients undergoing autologous hematopoietic cell transplantation (auto‐HCT). We assessed the feasibility of using chemical gustometry (CG) to measure dysgeusia and explored its associations with symptom burden, nutrition, chemotherapy pharmacokinetics (PK), oral microbiome. Methods conducted single‐center, prospective study (NCT03276481) multiple myeloma auto‐HCT. CG was performed longitudinally testing five flavors (sweet,...

10.1002/cncr.34444 article EN Cancer 2022-08-30

Earlier literature showed reduced efficacy of warfarin when co-administered with enteral nutrition formulas through feeding tubes. This study used an in vitro model for gastric administration a tube to evaluate potential causes absorption administered tubes.There were 2 phases the study. The first phase artificial stomach or without infusion formula. Warfarin was added contents either directly into vessel passed tube. tablet dissolution compared injectable formulation, which served as...

10.1177/0148607109337257 article EN Journal of Parenteral and Enteral Nutrition 2010-05-01

To determine whether cryopreserved solutions of the thrombolytic agent alteplase could be used as a safe, effective, and economically reasonable alternative to urokinase in patients presenting with occluded central venous access devices (CVADs).Alteplase has been reported an efficacious for treatment CVADs. However, practicality using choice this indication remained conjectural. make approach feasible, was diluted 1 mg/mL 2.5-mL aliquots were stored at -20 degrees C until use. A need confirm...

10.1200/jco.2002.07.131 article EN Journal of Clinical Oncology 2002-04-01

7559 Background: GL-ONC1 is an attenuated vaccinia virus genetically engineered with the insertion of RUC (luciferase)-GFP, LacZ (beta-galactosidase), and gusA (beta-glucuronidase) genes. We investigated feasibility, safety, recommended dose when administered intrapleurally. Methods: Pts pleural effusion from malignant mesothelioma (MPM), NSCLC, breast cancer, or other solid tumor, a free space were eligible. Single doses 1x107, 1x108, 1x109, 3x109 plaque forming units administered,...

10.1200/jco.2015.33.15_suppl.7559 article EN Journal of Clinical Oncology 2015-05-20

There is a witch‐hunt taking place today. Without deep understanding of the phenomena computer viruses legislators are attempting, both nationally and internationally, to prohibit what they do not understand. The virus misunderstood as concept abused term. Despite this rallying cry that all evil must be destroyed in same way witches were seen middle ages. uncritical criminalisation does lead better society nor it cure ills for which blamed. This paper defence but explore alternative uses...

10.1093/ijlit/11.2.162 article EN International Journal of Law and Information Technology 2003-06-01

Abstract Epidermal changes are histological hallmarks of secondary lymphedema, but it is unknown if keratinocytes contribute to its pathophysiology. Using clinical lymphedema specimens and mouse models, we show that play a primary role in development by producing T-helper 2 (Th2) -inducing cytokines. Specifically, find keratinocyte proliferation expression protease-activated receptor (PAR2) early responses following lymphatic injury regulate the Th2-inducing cytokines, migration Langerhans...

10.1101/2023.01.20.524936 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2023-01-21
Coming Soon ...